Biostar Pharmaceuticals Inc. Engaged Chief Scientist Professor Xiaohui Zheng To Preside Over The Company’s Product Development Projects

XIANYANG, China, August 27, 2014 /PRNewswire/– Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“Biostar” or “the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, announced today that the Company has hired Professor Xiaohui Zheng as its chief scientist to preside over the Company’s product development projects.

Professor Xiaohui Zheng, born in March 1968, is a professor and Director of the Engineering Research Center for the modernisation of Chinese herbal medicine at Northwestern University, and is mainly engaged in the traditional Chinese medicine compound effects of metabolism and composition analysis, biological chromatographic analysis of new technologies and innovative drug development.

In recent years, with key members of the Ministry of Science, he presided over a major new drug development, a chemical class of anti-cerebral ischemia DBZ drug, an anti-high altitude chemical class IDHP drugs study, earned national science and technology support program recognition for traditional Chinese medicine research, and other major scientific projects in China. At present, he has applied for seven Chinese patents, made five Chinese invention patents, submitted a PCT international patent application, and won the seventh Shaanxi Youth Science & Technology award amongst others.

The Company Chairman, Ronghua Wang, commented: “Professor Xiaohui Zheng is a senior academic expert with outstanding achievements in the research and development of traditional Chinese medicine, and is a rare talent, especially for liver cancer drugs. He has joined the Biostar R & D team for the development of new products, to enhance the Company’s R & D capabilities, and also to enhance the visibility of the academic community for the future development of the Company. He will guide the development of the Company’s product R & D team and will play a central role in promoting the strategic development of the Company,” he concluded.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company’s most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter (“OTC”) medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit:

Safe Harbor Relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company uses words and phrases such as “guidance,” “forecasted,” “projects,” “is expected,” “remain confident,” “will” and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company’s ability to sustain its sales effort going forward, its ability to retain existing and retain new customers for its products, its ability to achieve the projected sales through the efforts of the call center, to complete the contemplated clinical trials and capitalize on such opportunities, the Company’s ability to recover its sales and revenue for the gel capsule segment of its business, the state of consumer confidence and market demand or the Company’s products, success of our investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability including on account of our ability to manage growth, intense competition, wage increases in China, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, our ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2013, and other subsequent public filings. These filings are available at We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.